NR 567 Midterm (Latest 2026/2027) – Advanced Pharmacology | Grade A
Prepare for the NR 567 Midterm: Advanced Pharmacology with latest, verified
multiple-choice questions covering pharmacokinetics, pharmacodynamics,
cardiovascular pharmacology, antibiotics, endocrine management,
anticoagulation, and critical care pharmacology. Each question includes a bold
italic correct answer and a detailed bold italic explanation for fast, high-yield
review. Ideal for AGACNP students at Chamberlain University and other graduate
nursing programs seeking an updated, concise study guide for the NR 567
midterm exam.
Pharmacokinetics & Pharmacodynamics
1. A drug with a high first-pass effect is administered orally. Where is it
primarily metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
*Answer: C. Liver *
*Explanation: First-pass metabolism occurs in the liver. Kidneys excrete
drugs, lungs metabolize some drugs but not primary first-pass, and
stomach absorbs but does not significantly metabolize. *
2. A patient receives a drug with a half-life of 4 hours. Approximately how
many hours will it take to reach steady state?
A. 8 hours
,B. 12 hours
C. 20 hours
D. 40 hours
*Answer: C. 20 hours *
*Explanation: Steady state is reached in 4-5 half-lives (20 hours for 5 half-
lives). 8 hours is 2 half-lives, 12 hours is 3 half-lives, and 40 hours is 10
half-lives. *
3. Which parameter primarily determines a drug's volume of distribution
(Vd)?
A. Plasma protein binding
B. Tissue binding and lipid solubility
C. Renal clearance
D. Hepatic blood flow
*Answer: B. Tissue binding and lipid solubility *
*Explanation: Vd reflects how extensively a drug distributes into tissues.
High lipid solubility and tissue binding increase Vd, while high plasma protein
binding keeps drug in the vascular space and lowers Vd. *
4. A patient with severe hepatic failure requires a drug that undergoes
extensive hepatic metabolism. What pharmacokinetic change is most likely?
A. Increased clearance
B. Decreased half-life
C. Prolonged half-life
D. Reduced volume of distribution
*Answer: C. Prolonged half-life *
*Explanation: Hepatic failure reduces metabolic capacity, decreasing drug
clearance and prolonging half-life, which increases the risk of toxicity. *
,5. Which pharmacokinetic process describes movement of a drug from the
gastrointestinal tract into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
*Answer: B. Absorption *
*Explanation: Absorption is the movement of drug from the site of
administration into the bloodstream. Distribution is movement to tissues,
metabolism is biotransformation, and excretion is elimination. *
6. A medication with extensive hepatic first-pass metabolism is prescribed
orally. Which route would bypass first-pass metabolism?
A. Oral
B. Sublingual
C. Rectal (lower portion)
D. Both B and C
*Answer: D. Both B and C *
*Explanation: Sublingual and lower rectal administration bypass the portal
circulation, avoiding first-pass hepatic metabolism and increasing
bioavailability. *
7. What is the primary focus of pharmacokinetics in drug therapy?
A. The study of drug effects on the body
B. The study of drug absorption, distribution, metabolism, and excretion
C. The study of receptor binding
D. The study of therapeutic index
*Answer: B. The study of drug absorption, distribution, metabolism, and
excretion *
, *Explanation: Pharmacokinetics is the study of what the body does to a
drug, encompassing ADME: absorption, distribution, metabolism, and
excretion. *
8. Which statement best describes pharmacodynamics?
A. It describes the effects of a drug on the body and its mechanisms of action
B. It describes the movement of drugs through the body
C. It describes drug metabolism
D. It describes drug excretion
*Answer: A. It describes the effects of a drug on the body and its
mechanisms of action *
*Explanation: Pharmacodynamics is the study of what the drug does to the
body, including receptor interactions and dose-response relationships. *
9. A drug with a narrow therapeutic index requires what clinical
consideration?
A. No monitoring needed
B. Routine monitoring of drug levels
C. Higher doses for efficacy
D. Less frequent dosing
*Answer: B. Routine monitoring of drug levels *
*Explanation: A narrow therapeutic index means small changes in
concentration can cause toxicity or treatment failure, necessitating
therapeutic drug monitoring. *
10. How many half-lives are generally required to reach steady state?
A. 1-2
B. 3-4
C. 4-5
D. 10-12
Prepare for the NR 567 Midterm: Advanced Pharmacology with latest, verified
multiple-choice questions covering pharmacokinetics, pharmacodynamics,
cardiovascular pharmacology, antibiotics, endocrine management,
anticoagulation, and critical care pharmacology. Each question includes a bold
italic correct answer and a detailed bold italic explanation for fast, high-yield
review. Ideal for AGACNP students at Chamberlain University and other graduate
nursing programs seeking an updated, concise study guide for the NR 567
midterm exam.
Pharmacokinetics & Pharmacodynamics
1. A drug with a high first-pass effect is administered orally. Where is it
primarily metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
*Answer: C. Liver *
*Explanation: First-pass metabolism occurs in the liver. Kidneys excrete
drugs, lungs metabolize some drugs but not primary first-pass, and
stomach absorbs but does not significantly metabolize. *
2. A patient receives a drug with a half-life of 4 hours. Approximately how
many hours will it take to reach steady state?
A. 8 hours
,B. 12 hours
C. 20 hours
D. 40 hours
*Answer: C. 20 hours *
*Explanation: Steady state is reached in 4-5 half-lives (20 hours for 5 half-
lives). 8 hours is 2 half-lives, 12 hours is 3 half-lives, and 40 hours is 10
half-lives. *
3. Which parameter primarily determines a drug's volume of distribution
(Vd)?
A. Plasma protein binding
B. Tissue binding and lipid solubility
C. Renal clearance
D. Hepatic blood flow
*Answer: B. Tissue binding and lipid solubility *
*Explanation: Vd reflects how extensively a drug distributes into tissues.
High lipid solubility and tissue binding increase Vd, while high plasma protein
binding keeps drug in the vascular space and lowers Vd. *
4. A patient with severe hepatic failure requires a drug that undergoes
extensive hepatic metabolism. What pharmacokinetic change is most likely?
A. Increased clearance
B. Decreased half-life
C. Prolonged half-life
D. Reduced volume of distribution
*Answer: C. Prolonged half-life *
*Explanation: Hepatic failure reduces metabolic capacity, decreasing drug
clearance and prolonging half-life, which increases the risk of toxicity. *
,5. Which pharmacokinetic process describes movement of a drug from the
gastrointestinal tract into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
*Answer: B. Absorption *
*Explanation: Absorption is the movement of drug from the site of
administration into the bloodstream. Distribution is movement to tissues,
metabolism is biotransformation, and excretion is elimination. *
6. A medication with extensive hepatic first-pass metabolism is prescribed
orally. Which route would bypass first-pass metabolism?
A. Oral
B. Sublingual
C. Rectal (lower portion)
D. Both B and C
*Answer: D. Both B and C *
*Explanation: Sublingual and lower rectal administration bypass the portal
circulation, avoiding first-pass hepatic metabolism and increasing
bioavailability. *
7. What is the primary focus of pharmacokinetics in drug therapy?
A. The study of drug effects on the body
B. The study of drug absorption, distribution, metabolism, and excretion
C. The study of receptor binding
D. The study of therapeutic index
*Answer: B. The study of drug absorption, distribution, metabolism, and
excretion *
, *Explanation: Pharmacokinetics is the study of what the body does to a
drug, encompassing ADME: absorption, distribution, metabolism, and
excretion. *
8. Which statement best describes pharmacodynamics?
A. It describes the effects of a drug on the body and its mechanisms of action
B. It describes the movement of drugs through the body
C. It describes drug metabolism
D. It describes drug excretion
*Answer: A. It describes the effects of a drug on the body and its
mechanisms of action *
*Explanation: Pharmacodynamics is the study of what the drug does to the
body, including receptor interactions and dose-response relationships. *
9. A drug with a narrow therapeutic index requires what clinical
consideration?
A. No monitoring needed
B. Routine monitoring of drug levels
C. Higher doses for efficacy
D. Less frequent dosing
*Answer: B. Routine monitoring of drug levels *
*Explanation: A narrow therapeutic index means small changes in
concentration can cause toxicity or treatment failure, necessitating
therapeutic drug monitoring. *
10. How many half-lives are generally required to reach steady state?
A. 1-2
B. 3-4
C. 4-5
D. 10-12
